Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Participants who received tirzepatide also had greater improvements in metabolic risk ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications.

Researchers found GLP-1s may modestly reduce the risk of 14 obesity-related cancers, especially colorectal cancer, when compared to a weight-neutral medication used to treat diabetes.

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

The first development that occurred is that it evaluated its drug tirzepatide (Zepbound) against Novo Nordisk (NVO) Wegovy (Semaglutide ... the phase 3 ACHEIVE-1 study using oral GLP-1 receptor ...

Shares had skyrocketed after the introduction of Wegovy and diabetes ... more weight using competitor drug Zepbound, made by Eli Lilly of Indianapolis. The study, the first head-to-head comparison ...

On Sunday, a study published in the New England Journal of Medicine showed that people lost more weight using Wegovy competitor Zepbound, made by pharmaceutical company Eli Lilly. Eli Lilly funded ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy ... managers in the U.S. On Sunday a study was published in the New ...